^
No biomarker
Leiomyosarcoma
trabectedin
Sensitive: A1 - Approval
No biomarker
Leiomyosarcoma
eribulin mesylate
Sensitive: A2 - Guideline
No biomarker
Leiomyosarcoma
PTC596
Sensitive: B - Late Trials
Chr amplification(4)(q22.1)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
Chr del(3)(q14.2)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
Chr del(11)(q25)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
Chr del(2)(q14.1)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
Chr del(2)(p12)
Leiomyosarcoma
eribulin mesylate
Sensitive: C3 – Early Trials
Chr del(1)(q44)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
Chr amplification(8)(q13.2)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
Chr amplification(8)(q22.2)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
Chr amplification(13)(q13.3)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
Chr amplification(20)(p12.2)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
Chr amplification(4)(q26)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
ATRX mutation
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
TP53 mutation
Leiomyosarcoma
eribulin mesylate
Sensitive: C3 – Early Trials
ATRX mutation
Leiomyosarcoma
dacarbazine
Resistant: C3 – Early Trials
TP53 mutation
Leiomyosarcoma
dacarbazine
Resistant: C3 – Early Trials
AKT1 mutation + mTOR mutation
Leiomyosarcoma
TAK-228
Sensitive: C3 – Early Trials
TMB-H
Leiomyosarcoma
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
MYH9-ALK + ALK-WDR43
Leiomyosarcoma
crizotinib
Sensitive: C4 – Case Studies
PTEN mutation + TSC1 mutation
Leiomyosarcoma
TAK-228
Sensitive: C4 – Case Studies
NF1 mutation
Leiomyosarcoma
IPN60090
Sensitive: C4 – Case Studies
YWHAE-JAZF1 fusion
Leiomyosarcoma
regorafenib
Sensitive: C4 – Case Studies
PLK4 expression
Leiomyosarcoma
CFI-400945
Sensitive: D – Preclinical
CSPG4 overexpression
Leiomyosarcoma
CSPG4.TNK
Sensitive: D – Preclinical
HAT1 overexpression
Leiomyosarcoma
pazopanib
Resistant: D – Preclinical
MAN1A1-ROS1 rearrangement
Leiomyosarcoma
crizotinib
Sensitive: D – Preclinical